Impact of alcohol consumption on treatment outcome of hepatocellular carcinoma patients with viral hepatitis who underwent transarterial chemoembolization

Table 1 Baseline demographic data of patients with viral hepatitis only (group A) and those with viral hepatitis concurrent with alcohol consumption (group B)

Variables	Group A (n = 53), %	Group (n = 16), %	P value
Female sex	18 (34.0)	0 (0)	0.007
Age (yr): mean ± SD	56.1 ± 10.5	53.6 ± 7.5	0.365
Body mass index (kg/m2): mean ± SD	23.2 ± 4.3	22.0 ± 3.1	0.298
Underlying disease
Diabetic mellitus	10 (18.9)	2 (12.5)	0.718
Hypertension	9 (17.0)	2 (12.5)	1.000
Dyslipidemia	2 (3.8)	0 (0)	1.000
Hepatitis B virus infection	34 (64.2)	6 (37.5)	0.058
Hepatitis C virus infection	20 (37.7)	10 (62.5)	0.080
Hepatitis B and C virus coinfection	1 (1.9)	0 (0)	1.000
Cirrhosis	53 (100)	16 (100)	N/A
Child–Turcotte–Pugh classification			0.109
A	35 (66.0)	7 (43.8)
B	18 (34.0)	9 (56.2)
Presence of portal hypertension	36 (67.9)	10 (62.5)	0.687
Laboratory data
Hemoglobin (g/dL): mean ± SD	12.3 ± 1.9	12.2 ± 1.9	0.883
Platelet median (×103/mL): Median (IQR)	119 (78 to 208)	116 (64 to 175)	0.803
Serum creatinine (mg/dL): Median (IQR)	0.9 (0.7 to 1.0)	0.8 (0.7 to 0.9)	0.257
Serum Albumin (g/dL): mean ± SD	3.6 ± 0.7	3.2 ± 0.4	0.017
Total bilirubin (mg/dL): Median (IQR)	1.0 (0.6 to 2.0)	1.7 (0.9 to 2.1)	0.155
Aspartate aminotransferase (mg/dL), median (IQR)	63.0 (42.0 to 116.0)	96.5(73.5 to 155.0)	0.013
Alanine aminotransferase (mg/dL), median (IQR)	41.0 (23.0 to 76.0)	52.5 (45.0 to 85.0)	0.151
International normalized ratio: mean ± SD	1.2 ± 0.2	1.2 ± 0.4	0.654
Hepatitis B viral load (IU/mL): Median (IQR)	1450 (Undetectable to 165000)	32650 (13700 to 966000)	0.706
Alpha-fetoprotein (ng/mL): Median (IQR)	20.5 (9.3 to 499.8)	176.45 (13.3 to 992.2)	0.207
MELD: mean ± SD	9 (7 to 12)	11 (8 to 12)	0.307
ECOG score			1.000
0	42 (79.2)	13 (81.2)
1	11 (20.8)	3 (18.8)

SD: Standard deviation; IQR: Interquartile range; IU: International unit; MELD: Model for end-stage liver disease; ECOG: Eastern Cooperative Oncology Group; N/A: Not applicable.